Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial

Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial

  • Melior’s therapeutic candidate, tolimidone, is:  
    • Expected to mitigate the probability and severity of COVID-19 subjects developing sever lung complications 
    • A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies 

See more here

Comments are closed.